![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RINL |
Gene summary for RINL |
![]() |
Gene information | Species | Human | Gene symbol | RINL | Gene ID | 126432 |
Gene name | Ras and Rab interactor like | |
Gene Alias | RINL | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6ZS11 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
126432 | RINL | HCC1_Meng | Human | Liver | HCC | 2.22e-46 | 1.09e-01 | 0.0246 |
126432 | RINL | cirrhotic1 | Human | Liver | Cirrhotic | 3.74e-02 | 6.55e-02 | 0.0202 |
126432 | RINL | HCC1 | Human | Liver | HCC | 6.69e-11 | 1.56e+00 | 0.5336 |
126432 | RINL | HCC2 | Human | Liver | HCC | 5.04e-16 | 1.74e+00 | 0.5341 |
126432 | RINL | HCC5 | Human | Liver | HCC | 3.14e-08 | 1.03e+00 | 0.4932 |
126432 | RINL | S014 | Human | Liver | HCC | 2.31e-06 | 3.44e-01 | 0.2254 |
126432 | RINL | S015 | Human | Liver | HCC | 1.61e-10 | 5.10e-01 | 0.2375 |
126432 | RINL | S016 | Human | Liver | HCC | 3.45e-07 | 3.45e-01 | 0.2243 |
126432 | RINL | S027 | Human | Liver | HCC | 7.29e-05 | 6.33e-01 | 0.2446 |
126432 | RINL | S028 | Human | Liver | HCC | 1.37e-17 | 7.82e-01 | 0.2503 |
126432 | RINL | S029 | Human | Liver | HCC | 1.12e-12 | 5.97e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RINL | insertion | In_Frame_Ins | novel | c.1515_1516insCCCTCC | p.His505_Ile506insProSer | p.H505_I506insPS | Q6ZS11 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
RINL | insertion | Frame_Shift_Ins | novel | c.1513_1514insCTTTTCCTGGG | p.His505ProfsTer60 | p.H505Pfs*60 | Q6ZS11 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
RINL | SNV | Missense_Mutation | novel | c.700G>A | p.Glu234Lys | p.E234K | Q6ZS11 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RINL | insertion | Nonsense_Mutation | novel | c.1525_1526insTTACGTCGTTTTCGTAACATGTAATAACTAGGATGTAAATAAAAGTC | p.Tyr509PhefsTer6 | p.Y509Ffs*6 | Q6ZS11 | protein_coding | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
RINL | SNV | Missense_Mutation | c.788T>C | p.Val263Ala | p.V263A | Q6ZS11 | protein_coding | deleterious(0) | benign(0.185) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
RINL | SNV | Missense_Mutation | c.1523N>C | p.His508Pro | p.H508P | Q6ZS11 | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
RINL | SNV | Missense_Mutation | c.787G>A | p.Val263Ile | p.V263I | Q6ZS11 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RINL | SNV | Missense_Mutation | rs756901954 | c.1663N>C | p.Trp555Arg | p.W555R | Q6ZS11 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RINL | SNV | Missense_Mutation | c.1646N>A | p.Leu549Gln | p.L549Q | Q6ZS11 | protein_coding | tolerated(0.06) | benign(0.014) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
RINL | SNV | Missense_Mutation | c.1573N>T | p.Arg525Cys | p.R525C | Q6ZS11 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |